Does HAS-BLED risk score underestimate the risk of bleeding in patients with triple antithrombotic therapy?

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Atrial fibrillation (AF) patients frequently have coronary artery disease (CAD) and undergo percutaneous coronary interventions (PCI).
• Dual antiplatelet therapy (DAPT) is standard for acute coronary syndrome, while AF necessitates anticoagulation to prevent stroke.
• Combining these conditions often requires triple antithrombotic therapy (TAT) for optimal prevention of ischemic and thromboembolic events.

Purpose of the Study:

• To highlight the importance of triple antithrombotic therapy (TAT) in patients with atrial fibrillation (AF) and coronary artery disease (CAD).
• To discuss the role and limitations of the HAS-BLED score in assessing bleeding risk in patients on TAT.
• To emphasize the need for risk stratification that considers the nuances of dual versus triple antithrombotic strategies.

Main Methods:

• Review of current guidelines and clinical evidence regarding antithrombotic therapy in AF and CAD patients.
• Analysis of the utility and limitations of the HAS-BLED score in predicting bleeding events.
• Discussion of the components of triple antithrombotic therapy (e.g., DOACs, aspirin, clopidogrel).

Main Results:

• Triple antithrombotic therapy (TAT), typically direct oral anticoagulants (DOACs) plus aspirin and clopidogrel, is recommended for patients with AF undergoing PCI.
• The HAS-BLED score is a valuable tool for assessing bleeding risk in AF patients but does not differentiate between dual and triple antithrombotic regimens.
• Failure to distinguish between these regimens in risk assessment may impact the prevention of bleeding events.

Conclusions:

• Optimizing antithrombotic therapy in patients with both AF and CAD requires careful consideration of both ischemic and bleeding risks.
• The HAS-BLED score's limitations necessitate further refinement or complementary tools for precise bleeding risk assessment in the context of TAT.
• Personalized antithrombotic strategies are crucial for balancing efficacy and safety in this complex patient population.